NCT02222363终止1 期
A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Vivolux AB
- 入组人数
- 19
- 试验地点
- 3
- 主要终点
- Assessment of adverse event (AE) profile
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of the investigational drug VLX600 in patients with refractory advanced solid tumors.
详细描述
This Phase I, open label dose escalation study of VLX600 in patients with refractory advanced solid tumors will determine the safety profile and maximum tolerated dose (MTD) of VLX600 when administered by intravenous infusion on Days 1, 8, and 15 of each 28-day treatment cycle. Dose escalation will proceed according to the standard "3 + 3" design using doubling doses. The doses are: 10, 20, 40, 80, 160, and 210 mg VLX600.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women greater than or equal to 18 years of age.
- •Histologic evidence of advanced solid tumors (excluding central nervous system (CNS) primary tumors) non-resectable, refractory to standard therapies, or patient cannot receive or refuses standard therapy.
- •Solid tumors measurable according to RECIST 1.1 or solid tumors not measurable according to RECIST 1.1, but which express tumor markers (e.g., prostate cancer with prostate specific antigen (PSA) expression or ovarian cancer with cancer antigen-125 (CA-125) expression) are eligible.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or
- •Must have the following laboratory values, obtained less than or equal to 7 days prior to registration:
- •Absolute neutrophil count (ANC) greater than or equal to 1500/µL
- •Platelet (PLT) count greater than or equal to 100,000/µL
- •Total bilirubin less than 1.5 x upper normal limit (UNL)
- •Aspartate aminotransferase (AST) (SGOT) less than or equal to 3 x UNL
- •Creatinine less than 1.5 x UNL
- •Women of childbearing potential must have a negative serum pregnancy test less than or equal to 7 days prior to registration.
- •Life expectancy greater than 12 weeks.
- •Must provide written informed consent.
- •Must be willing to return to Mayo Clinic enrolling institution for follow-up.
排除标准
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes mellitus, seizure disorder or psychiatric illness/social situations that would limit compliance with study requirements.
- •Treatment with any of the following prior therapies:
- •Chemotherapy less than or equal to 4 weeks prior to registration
- •Mitomycin C/nitrosoureas less than or equal to 6 weeks prior to registration
- •Immunotherapy less than or equal to 4 weeks prior to registration
- •Biologic therapy less than or equal to 4 weeks prior to registration
- •Radiation therapy less than or equal to 4 weeks prior to registration
- •Non-cytotoxic therapy less than or equal to 5 half-lives prior to registration
- •Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment.
- •Major surgery less than 28 days prior to study entry.
- •Active other malignancy, except non-melanoma skin cancer or carcinoma-in-situ (e.g., of cervix, breast, prostate). If there is a history of prior malignancy, patient must not be receiving other specific treatment (other than hormonal therapy) for the cancer.
- •CNS metastases if not previously treated and stable for at least 2 months per imaging and clinical assessment.
- •Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- •Pregnant women
- •Nursing women
- •Men or women of childbearing potential unwilling to employ adequate contraception
- •Other concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-FDA-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
- •Cardiac issues consisting of either symptomatic congestive heart failure (NYHA Class II or higher), unstable angina pectoris, myocardial infarction within 6 months, and/or cardiac arrhythmia, including atrial fibrillation (which is symptomatic or requires treatment).
- •Corrected QT interval (QTc) interval greater than 450 msec (males) or greater than 470 msec (females).
- •Immunocompromised patients (other than that related to the use of corticosteroids) including patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •Clinically relevant retinal abnormalities as per the medical history or ophthalmologic findings in the pretreatment evaluation (e.g., retinitis pigmentosa or macular degeneration).
- •History of thromboembolism within the past 5 years, history of catheter-related thrombophlebitis or other clinically significant thrombophlebitis are excluded.
研究组 & 干预措施
VLX600
Experimental
Dose of VLX600 in patients with refractory advanced solid tumors
干预措施: VLX600 (Drug)
结局指标
主要结局
Assessment of adverse event (AE) profile
时间窗: AEs are assessed from first treatment day through at least 30 days after last treatment.
Determination of the maximum tolerated dose (MTD) of VLX600
时间窗: MTD will be determined during dose escalation phase of study, up to one year.
Determination of the recommended Phase II dose (RPTD) of VLX600
时间窗: Determination of RPTD will be based on adverse event profile, up to one year.
次要结局
- Description of the tumor response to VLX600 treatment(Tumor response will be evaluated by CT scans or MRI at pre-treatment baseline and on Cycle 2 Day 28, then after every 8 weeks, and then at off-study (if greater than 4 weeks since prior tumor assessment).)
- Description of progression-free survival(Progression-free survival is calculated from date of first treatment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 200 days (through 6 treatment cycles).)
- Description of the pharmacokinetics (PK) of VLX600(PK assessed in Cycle 1 only. Day 1: pre-dose, 15, 30, 60 min, and 2, 4, 4.25, 4.5, 5, 8 hrs post start of infusion. Day 2: 24 hr post-start of infusion. Day 8: pre-dose, Day 15 (same as Day 1), Day 16: 24 hr post-start of infusion, and Day 22: pre-dose)
- Description of overall survival.(Overall survival will be determined from date of first study treatment until death due to any cause, up to 72 weeks (duration of study).)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard TherapySolid TumorsNCT02499224CellabMED39
已完成
1 期
A Study of LY110140 in Healthy Japanese Male ParticipantsHealthy VolunteerNCT01569126Eli Lilly and Company56
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy SubjectsHealthy VolunteersPharmacokinetics of ASP7962NCT02136316Astellas Pharma Europe B.V.48
招募中
1 期
A Phase I Study of HS-10386 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05911464Jiangsu Hansoh Pharmaceutical Co., Ltd.248
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsAdvanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial Carcinoma, HCCEsophageal Squamous Cell CarcinomaSmall-cell Lung CancerCervical CancerMerkel Cell CarcinomaMesotheliomaPD-L1 Amplified Tumor (9p24.1)Cyclin-dependent Kinase 12 Mutated TumorsBasal Cell Carcinoma (Unresectable or Metastatic)Sarcomatoid Renal Cell CarcinomaClear Cell Ovarian or Endometrial CarcinomaAnal CarcinomaSquamous Cell Penile CarcinomaNasopharyngeal CarcinomaDNA Polymerase Epsilon Mutated Tumors (P286R and V411L)NCT04272034Incyte Corporation105